Discern has served as an advisor and subject matter expert for two large pharmaceutical clients’ separate multiple sclerosis (MS) quality and performance measurement initiatives. For one client, using a multi-pronged approach to measure development, implementation, and quality improvement, Discern has supported coordination of activities among stakeholders through national health care organizations including the Pharmacy Quality Alliance (PQA), the National Quality Forum (NQF), the American Academy of Neurology (AAN), and the Physician Consortium for Performance Improvement (PCPI). Through this collaboration, four MS measures concepts had been developed by PQA and are being field tested as electronic measure specifications.The measures are now being considered for testing as registry-based measures. One measure focuses on the use of Disease Modifying Therapy (DMT) and three measures focus on Magnetic Resonance Imaging (MRI) for MS care and treatment monitoring.With support from the same client, the NQF Measure IncubatorTM has been engaged to develop an MS patient-reported measure. Discern has also been engaged in advising related to uptake of the measures through implementation in programs. With support from another client, Discern has been involved in efforts to educate the MS patient advocacy community on the health care quality landscape, with a specific focus on quality measurement. The goal of the collective MS measurement work is improved care and outcomes for patients with MS.